Holy Stone Healthcare

Focus: Holy Stone Healthcare is a Taiwan-based biotechnology company founded in 2009 focused on small molecule development, primarily in oncology. The company operates at mid-stage with a modest pipeline of 5 active clinical programs.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Holy Stone Healthcare

AI assessmentNot Hiring

No open roles listed right now. Follow Holy Stone Healthcare to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CA102N

Advanced or Metastatic Colorectal Cancer (mCRC)

N/A

Clinical Trials (1)

NCT05274204Individual Patient Expanded Access to CA102N

N/A

Help build intelligence for Holy Stone Healthcare

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Oncology focus offers exposure to one of pharma's highest-priority therapeutic areas with significant unmet need
Early-stage pipeline (Phase 1-2) provides opportunity to influence clinical strategy and see molecules progress through development
Small team size (limited hiring: 7 active roles) suggests flatter structure with potential for greater individual impact

Watch Out For

No approved products or revenue-generating assets creates preclinical execution risk and unclear cash runway sustainability
Minimal public visibility (zero publications, no FDA approvals, limited news coverage) suggests early maturity or resource constraints
Only 1 regulatory affairs hire among 7 open roles signals possible underinvestment in regulatory infrastructure critical for trial advancement

Generated by Claude from Holy Stone Healthcare's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CA102N

Advanced or Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT03616574First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

Phase 1

IBD98-M:

Healthy

Phase 1

Clinical Trials (1)

NCT02196662Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers

Phase 1

CA102N

Metastatic Colorectal Cancer

Phase 2

Clinical Trials (1)

NCT06039202Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Phase 2

High dose

Colitis, Ulcerative

Phase 2

Clinical Trials (1)

NCT02493712A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2009

Portfolio: 5 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline